These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12647672)

  • 41. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
    Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
    Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atazanavir gets FDA Advisory Committee's thumbs-up.
    IAPAC Mon; 2003 Jun; 9(6):120. PubMed ID: 12951939
    [No Abstract]   [Full Text] [Related]  

  • 43. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 44. Emerging drugs in the fight against HIV disease.
    Rosenthal E
    HRSA Careaction; 2003 Feb; ():1-8. PubMed ID: 12739497
    [No Abstract]   [Full Text] [Related]  

  • 45. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 46. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Oct; 24(10):684. PubMed ID: 20929413
    [No Abstract]   [Full Text] [Related]  

  • 47. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
    Melby T; Despirito M; Demasi R; Heilek-Snyder G; Greenberg ML; Graham N
    J Infect Dis; 2006 Jul; 194(2):238-46. PubMed ID: 16779731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3TC receives full approval.
    Grodeck B; Vazquez E
    Posit Aware; 1997; 8(3):11. PubMed ID: 11364417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 51. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
    Bonjoch A; Negredo E; Puig J; Erkizia I; Puig T; Cabrera C; Ruiz L; Clotet B
    AIDS; 2006 Sep; 20(14):1896-8. PubMed ID: 16954734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug cost. States concerned about Fuzeon.
    AIDS Policy Law; 2003 Apr; 18(7):5. PubMed ID: 12728848
    [No Abstract]   [Full Text] [Related]  

  • 55. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 57. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

  • 58. FDA notifications. Tentative approval to Aptivus for combination ART.
    AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
    [No Abstract]   [Full Text] [Related]  

  • 59. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 60. David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
    Reddy D
    Lancet Infect Dis; 2003 Feb; 3(2):110-3. PubMed ID: 12560198
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.